ABSTRACT
On the other hand, and also in relation to medical applications, the effects that many nanostructures could have on health still remain unknown, challenging the Food and Drug Agency (FDA) in the United States or the European Medicines Agency (EMEA) to face continuous regulatory issues concerning the commercialisation of nanotechnology-based products3,4 and their eventual consumption, certainly slowing down the rate at which they would become available to the šnal consumer.
